TABLE II.

Patient Samplings by Treatment Phases

	Treatment Phase
	Induction	CNS	Intensification	Continuation	Post-Treatment
Study Patients
Overall trial population	491	491	491	491	491
Trial population at participating centers Ineligible for HRQL assessment (n)	375	375	375	375	375
<5 years of age	195	192	187	123	12
deceased	0	0	0	1	3
induction failure	4	4	4	4	4
relapse	0	0	0	8	39
transferred	0	1	1	1	1
Total ineligible	199	197	192	137	59
Eligible for HRQL assessment (n)	176	178	183	238	316
Missing HRQL assessment (n)
unknown reason	50	48	40	36	100
refusal	0	0	0	0	1
other	0	0	0	1	27
Total missing	50	48	40	37	128
Collected HRQL assessments (n)	126	130	143	201	188
Fully complete HRQL assessments (n)	121	124	137	196	171
male (%)	56.3*	59.2 *	55.9*	58.2*	58.5*
SR (%)	37.3**	40.0**	41.3**	47.3*	59.6*

CNS, central nervous system; HRQL, health-related quality of life; HR, high risk; n, number of patients; SR, standard risk;

^*p>0.05 for difference from overall trial population;

^**p<0.01 for difference from overall trial population.